NYXH Nyxoah

Publication relating to transparency notifications

Publication relating to transparency notifications

               

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), September 27, 2024, 8.00am CET / 2.00am ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

BlackRock, Inc.

On September 24, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons indicating that BlackRock Advisors, LLC went below the 3% threshold on September 20, 2024. As of such date, BlackRock, Inc. (together with its controlled undertakings) held 1,116,421 voting rights, consisting of 1,043,221 shares and 73,200 equivalent financial instruments, representing 3.25% of the total number of voting rights on September 20, 2024 (34,373,015).

The notification dated September 23, 2024 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • BlackRock, Inc. (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
    • BlackRock Advisors, LLC (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
    • BlackRock Fund Advisors (with address at 400 Howard Street, San Francisco, CA, 94105, U.S.A.)
    • BlackRock Investment Management (UK) Limited (with address at 12 Throgmorton Avenue, London, EC2N 2DL, U.K.)
    • BlackRock Investment Management, LLC (with address at 1 University Square Drive, Princeton, NJ, 8540, U.S.A.)
  • Date on which the threshold was crossed: September 20, 2024
  • Threshold that is crossed: 3%
  • Denominator: 34,373,015
  • Notified details:
A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
BlackRock, Inc.00 0.00% 
BlackRock Advisors, LLC1,071,5611,016,861 2.96% 
BlackRock Fund Advisors4646 0.00% 
BlackRock Investment Management (UK) Limited1,0801,080 0.00% 
BlackRock Investment Management, LLC25,24225,234 0.07% 
Subtotal1,097,9291,043,221 3.03% 
 TOTAL1,043,22103.03%0.00%



B) Equivalent financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
BlackRock Advisors, LLCSecurities Lent  72,3000.21%physical
BlackRock Fund AdvisorsSecurities Lent  9000.00%physical
 TOTAL  73,2000.21% 



 TOTAL (A & B)# of voting rights% of voting rights 
    1,116,4213.25% 
  • Full chain of controlled undertakings through which the holding is effectively held:



BlackRock, Inc.

Trident Merger, LLC

BlackRock Investment Management, LLC

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock International Holdings, Inc.

BR Jersey International Holdings L.P.

BlackRock Holdco 3, LLC

BlackRock Cayman 1 LP

BlackRock Cayman West Bay Finco Limited

BlackRock Cayman West Bay IV Limited

BlackRock Group Limited

BlackRock Finance Europe Limited

BlackRock Investment Management (UK) Limited

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Holdco 4, LLC

BlackRock Holdco 6, LLC

BlackRock Delaware Holdings Inc.

BlackRock Fund Advisors

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Capital Holdings, Inc.

BlackRock Advisors, LLC

  • Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock Advisors, LLC going below 3%.



*

* *

Contact:

Nyxoah

Loic Moreau, CFO



Attachment



EN
27/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.  Preliminary, Unaudited Second Quarter 2025 Financial Results and Business U...

 PRESS RELEASE

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre ...

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025  Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui certains résultats financiers préliminaires non audités pour le deuxième trimestre 2025 et d'autres informations su...

 PRESS RELEASE

Nyxoah Receives Approval from FDA for Genio® System for the Treatment ...

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep ApneaU.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food a...

 PRESS RELEASE

Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné...

Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du SommeilLancement Officiel de la Commercialisation aux États-Unis Mont-Saint-Guibert, Belgique – 8 juillet 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch